{"prompt": "['potential risk for adverse events in nursing infants secondary to treatment of the', 'mother with BV, breastfeeding should be discontinued if the mother is treated with', 'this chemotherapy.', '3.2.6 Current or history of known pulmonary fibrosis, chronic obstructive pulmonary', 'disease (COPD), emphysema, bronchiectasis, or diffuse or significant local', 'radiographic interstitial infiltrates on chest x-ray (CXR) or computed axial', 'tomography (CT) scan, that, in the opinion of the investigator, would exclude', 'bleomycin use.', 'NOTE: Participants with an abnormal CXR or CT scan (which may indicate', 'pulmonary KS) should undergo screening evaluations to rule out an infectious', 'cause, per standard of care. If available, other diagnostic procedures such as', 'bronchoscopy should be considered to confirm the presence or absence of', 'pulmonary KS and/or an infectious agent. These procedures should be', 'completed outside the study. These participants should be excluded if, in the', 'opinion of the site investigator, use of bleomycin would be detrimental.', '3.2.7 Oxygen saturation less than 90% and/or exercise desaturation greater than 4%', 'within 14 days before study enrollment.', \"NOTE: Exercise is defined as any activity that will increase a participant's resting\", 'heart rate by at least 20 beats/minute.', '3.3', 'Number of Participants to be Enrolled', '3.3.1', 'Proposed sample size', 'This study will enroll up to 20 participants.', '3.3.2', 'Accrual rate', 'Approximately 2 participants per month.', '3.4', 'Participant Enrollment Procedures', 'This protocol must be approved by the Institutional Review Board (IRB), the National', 'Institute for Medical Research (NIMR) in Tanzania, and the participating site must be', 'registered for study participation with the AMC Operations and Data Management Center', '(ODMC) before participant enrollment.', 'After it has been determined that the participant is eligible and an informed consent form', 'has been signed by the participant, the participant must be registered on-line via the AMC', 'Internet Data Entry System (Advantage eClinical). Enrollment and data collection will', 'occur via Advantage eClinical.', 'The participating site will ensure a participant meets all eligibility criteria prior to', 'completing the protocol-specific eligibility checklist in Advantage eClinical for', 'enrollment. Participants will be enrolled on-line via Advantage eClinical no more than 1', 'week prior to the initiation of treatment (enrollment 1 day prior to or on the day of treatment', 'is strongly encouraged). Once the eligibility checklist is submitted a system-generated', 'confirmation email will be sent to the enroller upon successful completion of the participant', 'enrollment. If the on-line system is inaccessible, the site should notify the AMC ODMC', '(via email at amipm@emmes.com or via phone at 301-251-1161) for further instructions.', 'AMC-S007 (Version 2.0) 20MAR2018', '16', 'NCI Version Date 20MAR2018']['4.0', 'TREATMENT PLAN', 'The treatment plan (Section 4.0) and dose modifications (Section 5.0) and clinical and', 'laboratory evaluations (Section 8.0) presented in this protocol represent the standard of', 'care for KS treatment at Bugando Medical Centre. As the primary aim of this investigation', 'is to assess quality of life, this treatment plan represents the general guidelines the site will', 'follow for patient care concurrent to survey assessments required by this protocol.', 'Excepting cases where enrolled participants do not receive any doses of standard of care', 'chemotherapy and therefore cannot be assessed for the effect of treatment on quality of', 'life, adherence to the treatment plan will not be assessed for this protocol.', '4.1', 'Treatment Administration', 'Standard treatment will be administered on an outpatient basis. Reported adverse events', 'and potential risks for bleomycin and vincristine are described in Section 6.0. Appropriate', 'dose modifications for bleomycin and vincristine are described in Section 5.0. No', 'investigational or commercial agents or therapies other than those described below may be', \"administered with the intent to treat the participant's malignancy.\", 'Table 4-A: Treatment Administration', 'Drug', 'Dose', 'Route', 'Schedule', 'Vincristine', '2', 'mg', 'in', '2mL', 'IV', 'over', '1', 'minute', 'Every 21 days for up', 'sulfate (V)', '(undiluted)', '(maximum 2 minutes)', 'to six cycles', '15 units/m\u00b2 in 50 mL', 'Bleomycin', '0.9% sodium chloride', 'IV over 10 minutes', 'Every 21 days for up', 'sulfate (B)', 'to six cycles', 'for injection', '4.1.1 Standard therapy dosing instructions', 'BV will be administered on day 1 of each 21-day cycle.', 'Each cycle of BV should be administered 21 days (=2 days) after the first day of', 'the previous cycle. BV must not be administered earlier than 19 days after the', 'previous cycle.', 'Treatment with BV will continue for six cycles, or until toxicity requiring', 'discontinuation of study chemotherapy, or the site investigator has determined that', 'alternative therapy is required, whichever occurs first.', '4.1.1.1 Vincristine sulfate will be administered at a dose of 2 mg (fixed dose) in a', 'volume of 2 mL over 1 minute into the sidearm of a rapidly flowing', 'intravenous infusion every 21 days (2 days) (see Section 5.2.2 for specific', 'instructions regarding dosage reduction for participants with elevated', 'bilirubin). The vincristine infusion will be followed by bleomycin as', 'detailed below.', '4.1.1.2 Vincristine should be administered before bleomycin if given in the same', 'IV line.', '4.1.1.3 Bleomycin sulfate will be administered at a dose of 15 units/m\u00b2 over 10', 'minutes every 21 days (=2 days) (see Section 5.3 for specific instructions', 'AMC-S007 (Version 2.0) 20MAR2018', '17', 'NCI Version Date 20MAR2018']\n\n###\n\n", "completion": "END"}